Athira Pharma Valuation
| ATHA Stock | USD 0.63 0.01 1.56% |
Athira Pharma is undervalued. Athira Pharma shows a prevailing Real Value of $2.3 per share. The current price of the firm is $0.63. Our model approximates the value of Athira Pharma from analyzing the firm fundamentals such as return on equity of -0.85, and Current Valuation of (42.72 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Athira Pharma's valuation include:
Price Book 0.4311 | Enterprise Value -42.7 M | Enterprise Value Ebitda 1.3057 |
Undervalued
Today
Please note that Athira Pharma's price fluctuation is extremely dangerous at this time. Calculation of the real value of Athira Pharma is based on 3 months time horizon. Increasing Athira Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Athira Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Athira Stock. However, Athira Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.63 | Real 2.3 | Target 7.33 | Hype 0.62 |
The real value of Athira Stock, also known as its intrinsic value, is the underlying worth of Athira Pharma Company, which is reflected in its stock price. It is based on Athira Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Athira Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Athira Pharma helps investors to forecast how Athira stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Athira Pharma more accurately as focusing exclusively on Athira Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Athira Pharma's intrinsic value based on its ongoing forecasts of Athira Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Athira Pharma's closest peers. If more than one evaluation category is relevant for Athira Pharma we suggest using both methods to arrive at a better estimate.
Athira Pharma Cash |
|
Athira Valuation Trend
Comparing Athira Pharma's enterprise value against its market capitalization is a good way to estimate the value of Athira Pharma uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Athira Pharma Total Value Analysis
Athira Pharma is presently forecasted to have valuation of (42.72 M) with market capitalization of 24.83 M, debt of 1.58 M, and cash on hands of 252.4 M. The negative valuation of Athira Pharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Athira Pharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(42.72 M) | 24.83 M | 1.58 M | 252.4 M |
Athira Pharma Asset Utilization
One of the ways to look at asset utilization of Athira is to check how much profit was generated for every dollar of assets it reports. Athira Pharma shows a negative utilization of assets of -0.48 percent, losing $0.004753 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Athira Pharma shows how unproductive it operates for each dollar spent on its assets.Athira Pharma Ownership Allocation
Athira Pharma holds a total of 38.67 Million outstanding shares. Over half of Athira Pharma's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Athira Pharma Profitability Analysis
Net Loss for the year was (117.67 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Athira Pharma's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Athira Pharma and how it compares across the competition.
About Athira Pharma Valuation
The stock valuation mechanism determines Athira Pharma's current worth on a weekly basis. Our valuation model uses a comparative analysis of Athira Pharma. We calculate exposure to Athira Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Athira Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -969 K | -1 M |
Athira Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 38 M |
Athira Pharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Athira Pharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Athira we look at many different elements of the entity such as Athira's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Athira Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Athira Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Athira Pharma's worth.Complementary Tools for Athira Stock analysis
When running Athira Pharma's price analysis, check to measure Athira Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Athira Pharma is operating at the current time. Most of Athira Pharma's value examination focuses on studying past and present price action to predict the probability of Athira Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Athira Pharma's price. Additionally, you may evaluate how the addition of Athira Pharma to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |